共 111 条
[1]
Sundar R(2014)Immunotherapy in the treatment of non-small cell lung cancer Lung Cancer 85 101-109
[2]
Soong R(2020)Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC) Cancer 126 260-270
[3]
Cho BC(2016)Predictive biomarkers for checkpoint inhibitor-based immunotherapy Lancet Oncol 17 e542-e551
[4]
Brahmer JR(2017)Tumor and microenvironment evolution during immunotherapy with nivolumab Cell 171 e16-1920
[5]
Soo RA(2016)Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial Lancet 387 1909-2454
[6]
Bodor JN(2012)Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2443-2426
[7]
Boumber Y(2017)First-line nivolumab in stage IV or recurrent non-small-cell lung cancer N Engl J Med 376 2415-17
[8]
Borghaei H(2018)Frameshift events predict anti-PD-1/L1 response in head and neck cancer JCI Insight 3 e98811-319
[9]
Gibney GT(2018)Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors Mol Cancer 17 129-4133
[10]
Weiner LM(2015)Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway For Immunopathol Dis Ther 6 7-4668